NCT02195076

Brief Summary

The investigators have developed an early detection solution for lung and breast cancer. A system which can distinguish between different medical odors based on biosensors. Our product is user-friendly noninvasive, nonradioactive and nontoxic to the patients. The technology enables a high level of sensitivity and provides users with a quick lab response and a simple yes or no answer. The aim of this study is to contribute and detect the patient at the earliest possible stage, in a noninvasive, nonradioactive and nontoxic way. Exhaled breath and urine samples are a promising approach towards future possible lung and breast cancer screening method.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

July 16, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 21, 2014

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Last Updated

July 21, 2014

Status Verified

July 1, 2014

Enrollment Period

3 years

First QC Date

July 16, 2014

Last Update Submit

July 17, 2014

Conditions

Keywords

Lung cancerBreast CancerBiosensorsVolatile Organic CompoundsOdorUrine SampleExhaled Breath Samples

Outcome Measures

Primary Outcomes (1)

  • The sensitivity and specificity of our biosensors in lung and breast cancer detection

    We will measure the ability of our biosensors to detect lung and breast cancer in urine samples from patients. Each urine sample will be subjected to 5 biosensors. If 3 out of 5 will report positively, the sample will be marked as cancerous. Each type of cancer (lung or breast) will be detected by different groups of biosensors, trained specifically to detect the specific cancer type. After the data of the detections will be collected, statistical analysis will be calculated in order to evaluate the sensitivity and specificity of our biosensor in cancer detection.

    3 years

Secondary Outcomes (1)

  • Testing the ability of our biosensors to distinguish between different sub- types of breast and lung cancer.

    3 years

Study Arms (3)

Breast Cancer patients

Other: non-invasive detection of cancer odor

Lung cancer patients

Other: non-invasive detection of cancer odor

Healthy controls

Other: non-invasive detection of cancer odor

Interventions

The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).

Breast Cancer patientsHealthy controlsLung cancer patients

Eligibility Criteria

Age30 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Breast Cancer patient after diagnosis. Lung Cancer patients after diagnosis. Healthy controls, matching gender and age.

You may qualify if:

  • Diagnosed Lung Cancer patients
  • Diagnosed Breast Cancer patients

You may not qualify if:

  • Cancer patients who were treated using chemotherapy
  • Cancer patients who were treated using radiation
  • Cancer patients who were treated using biological treatments
  • Cancer patients who were treated with chemotherapy
  • Cancer patients who were treated with any anti- cancer therapies
  • Cancer patients who use drugs that affect the immune system

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheba Medical Center

Tel Hashomer, Ramat- Gan, 52621, Israel

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

urine samples and exhaled breath samples

MeSH Terms

Conditions

Lung NeoplasmsBreast Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Michal Mark Danieli, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2014

First Posted

July 21, 2014

Study Start

July 1, 2014

Primary Completion

July 1, 2017

Last Updated

July 21, 2014

Record last verified: 2014-07

Locations